anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an anticancer slow-release agent (preferably slow-release injection) loading angiogenesis inhibitor and synergist thereof at the same time. The agent is composed of slow-release microspheres and a solvent, wherein the slow-release microsphere contains an anticancer-effective component and a slow-release adjuvant and the solvent is a special solvent containing suspending agent. The viscosity of the suspending agent is in the range from 100 cp to 3000 cp and the suspending agent is preferably sodium carboxymethylcellulose. The anticancer-effective component is the composition of an angiogenesis inhibitor and a synergist thereof selected from an antimitotic agent and an alkylating agent. The slow-release adjuvant is selected from poly-D,L-lactic acid and glycolic acid copolymer thereof, polyethylene glycol and poly(lactic acid) copolymer, carboxyl-terminated poly(lactic acid) copolymer, EVAc, and fatty acid-sebacic acid copolymer. The slow-release microsphere is also formulated as the slow-release implant. After the intratumoral or peritumoral injection or implantation, the slow-release agent can release the drug locally for about 40 days. Accordingly, the slow-release agent can be used alone or in combination with non-operative treatment such as chemotherapy and/or radiotherapy, and can selectively increase the local blood drug concentration in the tumor and significantly enhance the curative effect of the non-operative treatment such as chemotherapy.
Daily PO-NTX (50 mg, up to 100 mg if heavy drinking continues) Subjects randomized to PO-NTX will receive a study prescription (first one in the hospital)(fillable only at the medical center research pharmacy and prepared by the research pharmacist) for a 1-month supply of oral NTX to be taken once daily- 25 mg a day for 3 days, then 50 mg a day. If the subject has a prior history of taking PO-NTX and tolerating it well, the participant may be started at 50 mg. The dose may be increased to 100 mg daily for any participant who continues to have heavy drinking.
Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (\>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.
The method for prophylactic treatment of chronic hepatitis C includes clinical examination, diagnosis and treatment. Additionally, the mixture is prepared by adding 50.0-150.0 g of dried dogrose fruits, 10.0-20.0 g of dried milled watermelon peels, 10.0-30.0 g of dried flowers of Saint-John's-wort, 10.0-30.0 g of ground dried nettle leaves, 3.0-10.0 of dried dandelion flowers, and 1.0-7.0 g of mumiyo to 0.5 liters of water. The mixture is gradually set to boiling and boiled for 30 minutes. Then the mixture is slowly cooled, filtered, and the fluid is decanted. The dense mass is again boiled. Then to the mixture, 3.0-15.0 g of sunflower honey and 100.0-200.0 g of refined sugar is added. The mixture is again boiled until the dense viscous syrup-like mass. Then the mixture is cooled. The mixture is taken in 30 min preceding the meals, one tea-spoon, 2-3 times a day for 20-21 days. The result is evaluated clinically.
This disclosure is directed to improved opthalmological surgical procedures on the human eyeball characterized by initially utilizing ultra-pure hyaluronic acid in the form of a solution containing the sodium salt thereof, in a sufficient concentration thereof to protect delicate eye tissue and cells, e.g., 0.5 to 1.0 wt. % and higher, and thereafter, significantly diluting the concentration thereof in the aqueous media (natural and/or synthetic) within the anterior segment of the eye viz, in situ, so as to arrive at a concentration of said sodium salt of hyaluronic acid of less than 0.5 wt. % and more usually from about 0.1 to about 0.3 wt. % prior to closure. Hence a significant dilution from the initial higher concentrations by a factor of at least about 2:1 and more usually from about 3:1 to about 10:1 is effected. Hence the concentration of said sodium hyaluronate in the natural and/or synthetic aqueous media left within the eyeball at the surgical site after closure of the procedure ranges from about 0.1 to about 0.3 wt. % in the anterior chamber.
Group 2 (Intensive Insulin Therapy). Continuous intravenous insulin infusion was adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 to 120 mg/dl. Patients were submitted to capillary glycemic measurements every 2 hours. The insulin dose was adjusted according to an algorithm run by nurses and overseen by physicians. These patients received glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids (Diason, Nutricia Clinical Care Ltd).
1. Technical Result Widening of assortment of means for treatment of mastitis and extension of effective life. 2. Essence St.-John's wort Hypericum perforatum L. and roots of sweet cherries tree Cerasus avum are dried, comminuted, mixed in weight proportion 1:1-10 and boiled during 3 hours under proportion of raw and water 1:2-4. 3. Field of Application Medicine.
1. Use of natural human α-interferon for the preparation of a medicament in liquid form to be administered through peroral route at dosages comprised between 100 UI and 500 UI/day, for therapy of viral hepatitis in humans and animals. 2. Use of natural human α-interferon according to claim 1 wherein said interferon is obtained from lymphoblastoid cell cultures. 3. Use of natural human α-interferon according to claim 1 wherein said interferon is obtained from lymphocyte cells. 4. Use of natural human α-interferon according to any of previous claims wherein said medicament is administered in mono dosage units of appr. 1 ml. 5. Pharmaceutical liquid composition for peroral administration comprising natural human α-interferon either from lymphoblastoid cell cultures or from lymphocyte cells at a concentration between 100 UI/ml and 500 UI/ml for therapy of viral hepatitus in humans and animals.
Patients receive oral eflornithine (DFMO) and oral sulindac once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
Moderate-vigorous intensity strength exercise. 50 minutes per session, 2 times per week, 8 weeks.
PURPOSE:A composition for integument, consisting of a film-forming high polymer, a water absorbing high polymer and a chemical having the physiological activity as principal components. CONSTITUTION:A composition for integument, consisting of a film-forming high polymer, e.g. polyvinyl alcohol or acrylic acid, except nylon resin, a water absorbing high polymer, e.g. gelatin, agar, plantain seed, crosslinked gelatin, polymer prepared by introducing another high polymer into a synthetic water- soluble backbone high polymer or a synthetic high polymer having hydrophilic and hydrophobic segments, and a chemical having the physiological activity, e.g. a germicide, local anesthetic, antihistaminic agent, anti-inflammatory and analgesic agent or antibiotic substance, as principal components, and used as an external anti-inflammatory and analgesic agent, external dermatopathic drug, plaster, adhesive, etc. The composition is formulated into the film, sheet or liquid form, but preferably in the form of a sheet used as a pharmaceutical film. The composition has a high water vapor transmission and will cause little maceration and eruption in use for a long term.
BACKGROUND: There is no standard method for assembling the femoral head onto the femoral stem during total hip arthroplasty (THA). This study aimed to measure and record dynamic 3-dimensional (3D) THA head-neck assembly loads from residents, fellows, and attending surgeons, for metal and ceramic femoral heads.
METHODS: An instrumented apparatus measured dynamic 3D forces applied through the femoral stem taper in vitro for 31 surgeons (11 attendings, 14 residents, 6 fellows) using their preferred technique (ie, number of hits or mallet strikes). Outcome variables included peak axial force, peak resultant force, impulse of the resultant force, loading rate of the resultant force, and off-axis angle. They were compared between femoral head material, surgeon experience level, and the number of hits per trial.
RESULTS: Average peak axial force was 6.92 ± 2.11kN for all surgeons. No significant differences were found between femoral head material. Attendings applied forces more "on-axis" as compared to both residents and fellows. Nine surgeons assembled the head with 1 hit, 3 with 2 hits, 14 with 3 hits, 2 with 4 hits, and 3 with ≥5 hits. The first hit of multihit trials was significantly lower than single-hit trials for all outcome measures except the off-axis angle. The last hit of multihit trials had a significantly lower impulse of resultant force than single-hit trials.
CONCLUSION: Differences in applied 3D force-time curve dynamic characteristics were found between surgeon experience level and single and multihit trials. No significant differences were found between femoral head material.
The phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells, preferably beta cells, is provided. Preferably, the protection of pancreatic islets cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient. Preferably, the protection of pancreatic islet cells supports the treatment of diabetic or pre-diabetic patients, wherein the patient has or is pre-disposed to type 1 or type 2 diabetes or gestational diabetes. The THCV may be used in combination with one or more additional anti-diabetic agents such as metformin and/or anti-obesity agents. The THCV may be in the form of a synthetic cannabinoid, an isolated cannabinoid or as an extract from a cannabis plant such as a botanical drug substance. Preferably, the THCV when present in the form of a botanical drug substance is substantially free of the phytocannabinoids tetrahydrocannabinol (THC) and/or cannabidiol (CBD). THCV for use in the treatment of type 1 diabetes is also outlined.
Left atrial (LA) structures, including the accessory left atrial appendage (aLAA) and left atrial diverticulum, have been studied based on their prevalence, shape, and association with arrhythmia and thrombi formation. A pooled prevalence with morphometric data has not been determined in previous research. Our goal is to provide structured, clinically relevant information on said structures for clinical practitioners to use in their daily work. We propose that morphometric data of additional LA structures is necessary when considering the possible complications during cardiac interventions. We conducted a meta-analysis of all relevant studies which used electrocardiogram (ECG)-gated computed tomography (CT) imaging to determine the prevalence of LA structures and record their morphometric characteristics as well as the presence of thrombi. Data were extracted from 19 studies (n = 6643 hearts). The pooled prevalence estimate of left atrial diverticulum and/or aLAAs were reported from 14 studies and was 28.8%. The most common location noted was anterosuperior in the LA with 70.2% of structures found there. Data regarding thrombi presence in left atrial diverticulums or aLAAs were extracted from 11 studies and a thrombus was present in 0.2%. The prevalence rates of aLAAs and left atrial diverticulums are essential in performing uncomplicated cardiac interventions and reducing risk of electrophysiological procedures. Our findings show a considerable prevalence of LA structures in varying populations, provides information regarding the general characteristics of said structures, and does not support the previously theorized associated risk of thrombus formation in relation to LA structure presence.
For the past 6 decades, children have been going through cardiac surgery to correct congenital heart defects. Over the years, there has been great improvement in morbidity and mortality post cardiac surgery due to better technical skill and post operative treatment. Most of those surgeries require cardio-pulmonary bypass machine, which requires the use of blood products, and many of those children also require blood product as part of the post operative care, especially those children with cyanotic heart defects. Many toddlers and children are released home with relatively low hemoglobin levels, and with no careful follow up, at an age at which anemia is a risk factor for developmental delay and decreased cognitive function. Iron deficiency is common in Israel among children aged 6-24 months. At this age, breast milk and its substitute do not provide enough iron, and parents are not adherent enough to iron supplements as recommended by the ministry of health. Due to these facts, there is high importance, especially in children suffering from heart defects, for close follow up on their hemoglobin levels. In adults, a study following hemoglobin levels post cardiac surgery during hospitalization only, showed that most (79%) starting showing improvement during their hospitalization. Another study in patients over the age of 50 post coronary artery bypass graft, showed no difference between a group receiving iron supplements and another not receiving any, after 2 months. Similar studies were never done with children.
Participants in this arm will participate in a football training session for 60 minutes. During the training the participans will execute the warm-up process, the part of soccer technical exercises and they will play a small-side-game.
BACKGROUND: Variations in the innate and adaptive immune response systems are linked to variations in the severity of COVID-19. Natural killer cell (NK) function is regulated by sophisticated receptor system including Killer-cell immunoglobulin-like receptor (KIR) family. We aimed to investigate the impact of possessing certain KIR genes and genotypes on COVID19 severity in Iranians. KIR genotyping was performed on 394 age/sex matched Iranians with no underlying conditions who developed mild and severe COVID- 19. The presence and/or absence of 11 KIR genes were determined using the PCR with sequence specific primers (PCR-SSP).
RESULTS: Patients with mild symptoms had higher frequency ofKIR2DS1 (p = 0.004) and KIR2DS2 (p = 0.017) genes compared to those with severe disease. While KIR3DL3 and deleted variant of KIR2DS4 occurred more frequently in patients who developed a severe form of the disease. In this study, a significant increase of and B haplotype was observed in the Mild group compared to the Severe group (respectively, p = 0.002 and p = 0.02). Also, the prevalence of haplotype A was significantly higher in the Severe group than in the Mild group (p = 0.02).
CONCLUSIONS: These results suggest that the KIR2DS1, KIR2DS, and B haplotype maybe have a protective effect against COVID-19 severity. The results also suggest the inhibitory gene KIR2DL3 and haplotype A are risk factors for the severity of COVID-19.
<P>PROBLEM TO BE SOLVED: To provide a transcriptional regulatory DNA.  <P>SOLUTION: A genom DNA region containing a sequence of about 4.0 kb on the upstream of a MEGSIN gene is separated and the base sequence is determined. A region positively regulating the transcription region is specified in the genom DNA region. An AP-1 bond motif in the region is found to exhibit an activity to positively regulate the transcription activity. The transcription activity is considerably lowered by deleting the sequence or transducing a variation from/into the sequence by a site-specific mutagenesis. The transcriptional regulatory DNA is useful as a transcriptional regulatory sequence specific to mesangium cell. The DNA is useful also as a transcriptional factor for controlling the expression of MEGSIS gene and the screening of medicines.  <P>COPYRIGHT: (C)2004,JPO
Participants randomized to the delayed cervical spine focused treatment group will only receive the standard concussion care (individualized to their needs) 1x/week for the initial 4 weeks. At the 4-week timepoint, the cervical spine focused treatment will be added to the standard concussion care at a frequency of twice a week for 4 weeks. Should a participant be cleared for return to activity prior to the end of the 4-week period, cervical spine focused treatment will be suspended. The maximum total treatment duration is 8 weeks; 1x/week for weeks 1-8 for the standard concussion care and 2x/week for weeks 4-8 for the cervical spine focused treatment.
PROBLEM TO BE SOLVED: To obtain an austenitic steel alloy having corrosion resistance, toughness and non-magnetism and being compatible to use for human skin and the interior of human body by limiting the composition of elements of steel alloy to a specified range. SOLUTION: This alloy consists of, by weight, <=0.3% C, 2-26% Mn, 11-24% Cr, >2.5% to 10% Mo, 0-8% W, >0.55% to 1.2% N and the balance Fe with the others. Ni is not contained intentionally or limited to 0.5% at most. Si as an impurity is limited to 2% as the maximum content. This alloy has high contents in Mo, W, N and Cr, and so has remarkably high corrosion resistance. Since the alloy accordingly has a very low solubility in fluid and sweat of human body, it has a very small emission of ion onto human body. In consequence, the alloy is especially suitable for the purpose of avoiding nickel allergy in use on or inside human body. It is available, for example, for personal outfittings, medical instruments and materials, hand rails and the like.
In the intervention, the n-back task involving working memory in terms of its content updating was applied. This task is based on the continuous presentation of items (letters in this study) that appear and disappear one by one. During each presentation, the participant must judge whether the currently displayed item matches the item presented 'n' trials earlier. The n-back task used in the current study was computerized and was programmed in PsychoPy software. All participants started their training from the 1-back level. The training was adaptive, meaning that, according to the performance accuracy achieved, participants progressed to higher (or dropped to lower) levels of difficulty. The increasing/decreasing difficulty was based on a rise/fall in the 'n' parameter. Participants were involved in 12 sessions, three in each of the four weeks. Each session lasted approximately 45 minutes.
Obesity is an important risk factor for the development of pregnancy complications. We investigated the effects of pregestational overweight and obesity on maternal lipidome during pregnancy and on newborns' characteristics. The study encompassed 131 pregnant women, 99 with pre-pregnancy body mass index (BMI) < 25 kg/m2 and 32 with BMI ≥ 25 kg/m2. Maternal lipid status parameters, plasma markers of cholesterol synthesis and absorption and sphingolipids were determined in each trimester. Data on neonatal height, weight and APGAR scores were assessed. The results showed a higher prevalence (p < 0.05) of pregnancy and childbirth complications among the participants with elevated pregestational BMI. Levels of total cholesterol, HDL-cholesterol (p < 0.05) and LDL-cholesterol (p < 0.01) were significantly lower, and concentrations of triglycerides were higher (p < 0.05) in women with increased pre-gestational BMI. Lower concentrations of the cholesterol synthesis marker, desmosterol, in the 2nd trimester (p < 0.01) and the cholesterol absorption marker, campesterol, in each trimester (p < 0.01, p < 0.05, p < 0.01, respectively) were also found in this group. Markers of maternal cholesterol synthesis were in positive correlation with neonatal APGAR scores in the group of mothers with healthy pre-pregnancy weight but in negative correlation in the overweight/obese group. Our results indicate that gestational adaptations of maternal lipidome depend on her pregestational nutritional status and that such changes may affect neonatal outcomes.
The invention comprises lipo-polysaccharides obtainable by cultivating bacteria of the species Proteus vulgaris or mirabilis aerobically on a fully synthetic nutrient medium and either (a) dialysing the separated cell material, treating the non-dialysable material with a phenol-water mixture at an elevated temperature, extracting the aqueous phase with ether, and dialysing the aqueous phase, if desired after precipitating its valuable content with ethanol, and, if desired, purifying the material; or (b) dialysing the culture medium freed from cell material, precipitating the aqueous solution freed from insoluble material with ethanol, dialysing the precipitated material and fractionating it with ethanol, acetone or quaternary ammonium compounds containing a high molecular weight aliphatic radical and being soluble in water and ethanol, and, if desired, purifying the material.  The acylated lipo-polysaccharides derived by treatment of the above products with acylating agents introducing the radical of aliphatic carboxylic acids having 1-4 carbon atoms, are also novel compounds.  The lipopolysaccharides are of high molecular weight, possess no substantial antigenic and pathogenic activity but are active in leucocyte emigration tests and show antilipemic activity.  They have a sugar content of at least 20%, phosphorus content of at least 1,7% and a sedimentation constant of 1,9 X 10-13.  The novel compounds are used in pharmaceutical preparations (see Group VI).ALSO:Pharmaceutical preparations for topical, enteral or parenteral administration contain one or more lipo-polysaccharides obtainable by cultivating bacteria of the species Protens vulgaris or mirabilis aerobically on a fully synthetic nutrient medium, and acylated products derivable from said lipo-polysaccharides by treatment with acylating agents introducing the radical of an aliphatic carboxylic acid having 1 to 4 carbon atoms, (for preparation see Group IV(a)), in admixture with solid or liquid pharmaceutical carriers.  The preparations may be used in the form of creams, salves, tablets, dragees, capsules, pearls, solutions, suspensions, or emulsions.  They may be sterilized and/or contain preserving, stabilizing, wetting or emulsifying agents, salts, buffers or other therapeutically active substances.  They contain the lipo-polysaccharides in an amount of 0,001g -100g  per dosage unit.
FAST is a standardized passive auditory stimulation protocol. The patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. The FAST protocol is provided on compact discs (CDs), using portable players and noise cancelling headphones, while patients were awake (ie, eyes open). Speakers were used for one patient not tolerating his headphones. The CDs were identical according to track duration, labeling, and administration procedures.